The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Denton, C.P.; Khanna, D. Systemic sclerosis. Lancet 2017, 390, 1685–1699. [Google Scholar] [CrossRef]
- Dowson, C.; Simpson, N.; Duffy, L.; O’Reilly, S. Innate Immunity in Systemic Sclerosis. Curr. Rheumatol. Rep. 2017, 19, 2. [Google Scholar] [CrossRef]
- Fullard, N.; O’Reilly, S. Role of innate immune system in systemic sclerosis. Semin. Immunopathol. 2015, 37, 511–517. [Google Scholar] [CrossRef]
- O’Reilly, S.; Ciechomska, M.; Cant, R.; Hügle, T.; van Laar, J.M. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev. 2012, 23, 99–107. [Google Scholar] [CrossRef]
- Varga, J.; Abraham, D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J. Clin. Investig. 2007, 117, 557–567. [Google Scholar] [CrossRef]
- Brinckmann, J.; Kim, S.; Wu, J.; Reinhardt, D.P.; Batmunkh, C.; Metzen, E.; Notbohm, H.; Bank, R.A.; Krieg, T.; Hunzelmann, N. Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: Important pathogenetic steps in early and late stage of systemic scleroderma? Matrix Biol. 2005, 24, 459–468. [Google Scholar] [CrossRef]
- Allanore, Y.; Simms, R.; Distler, O.; Trojanowska, M.; Pope, J.; Denton, C.P.; Varga, J. Systemic sclerosis. Nat. Rev. Dis. Primers 2015, 1, 15002. [Google Scholar] [CrossRef]
- Ushach, I.; Burkhardt, A.M.; Martinez, C.; Hevezi, P.A.; Gerber, P.A.; Buhren, B.A.; Schrumpf, H.; Valle-Rios, R.; Vazquez, M.I.; Homey, B.; et al. METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages. Clin. Immunol. 2015, 156, 119–127. [Google Scholar] [CrossRef]
- Li, Z.Y.; Fan, M.-B.; Zhang, S.-L.; Qu, Y.; Zheng, S.-L.; Song, J.; Miao, C.-Y. Intestinal Metrnl released into the gut lumen acts as a local regulator for gut antimicrobial peptides. Acta Pharmacol. Sin. 2016, 37, 1458–1466. [Google Scholar] [CrossRef]
- Rao, R.R.; Long, J.Z.; White, J.P.; Svensson, K.J.; Lou, J.; Lokurkar, I.; Jedrychowski, M.P.; Ruas, J.L.; Wrann, C.D.; Lo, J.C.; et al. Meteorin-like Is a Hormone that Regulates Immune-Adipose Interactions to Increase Beige Fat Thermogenesis. Cell 2014, 157, 1279–1291. [Google Scholar] [CrossRef]
- Ushach, I.; Arrevillaga-Boni, G.; Heller, G.N.; Pone, E.; Hernandez-Ruiz, M.; Catalan-Dibene, J.; Hevezi, P.; Zlotnik, A. Meteorin-like/Meteorin-β Is a Novel Immunoregulatory Cytokine Associated with Inflammation. J. Immunol. 2018, 201, 3669–3676. [Google Scholar] [CrossRef]
- Bridgewood, C.; Russell, T.; Weedon, H.; Baboolal, T.; Watad, A.; Sharif, K.; Cuthbert, R.; Wittmann, M.; Wechalekar, M.; McGonagle, D. The novel cytokine Metrnl/IL-41 is elevated in Psoriatic Arthritis synovium and inducible from both entheseal and synovial fibroblasts. Clin. Immunol. 2019, 208, 108253. [Google Scholar] [CrossRef]
- Rupérez, C.; Ferrer-Curriu, G.; Cervera-Barea, A.; Florit, L.; Guitart-Mampel, M.; Garrabou, G.; Zamora, M.; Crispi, F.; Fernandez-Solà, J.; Lupón, J.; et al. Meteorin-like/Meteorin-β protects heart against cardiac dysfunction. J. Exp. Med. 2021, 218, e20201206. [Google Scholar] [CrossRef]
- Jung, T.W.; Pyun, D.H.; Kim, T.J.; Lee, H.J.; Park, E.S.; Abd El-Aty, A.M.; Hwang, E.J.; Shin, Y.K.; Jeong, J.H. Meteorin-like protein (METRNL)/IL-41 improves LPS-induced inflammatory responses via AMPK or PPARδ–mediated signaling pathways. Adv. Med. Sci. 2021, 66, 155–161. [Google Scholar] [CrossRef]
- Wullschleger, S.; Loewith, R.; Hall, M.N. TOR signaling in growth and metabolism. Cell 2006, 124, 471–484. [Google Scholar] [CrossRef]
- Liu, J.; Diao, L.; Xia, W.; Zeng, X.; Li, W.; Zou, J.; Liu, T.; Pang, X.; Wang, Y. Meteorin-like protein elevation post-exercise improved vascular inflammation among coronary artery disease patients by downregulating NLRP3 inflammasome activity. Aging 2023, 15, 14720–14732. [Google Scholar] [CrossRef]
- de Almeida, A.R.; Dantas, A.T.; de Oliveira Gonçalves, M.E.; Chêne, C.; Jeljeli, M.; Chouzenoux, S.; Thomas, M.; Cunha, E.G.; de Azevedo Valadares, L.D.; de Melo Gomes, J.V.; et al. PPARγ partial agonist LPSF/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients. Inflammopharmacology 2024, 32, 433–446. [Google Scholar] [CrossRef]
- Ghosh, A.K.; Bhattacharyya, S.; Wei, J.; Kim, S.; Barak, Y.; Mori, Y.; Varga, J. Peroxisome proliferator-activated receptor-γ abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J. 2009, 23, 2968–2977. [Google Scholar] [CrossRef]
- Ji, H.; Dong, H.; Lan, Y.; Bi, Y.; Gu, X.; Han, Y.; Yang, C.; Cheng, M.; Gao, J. Metformin attenuates fibroblast activation during pulmonary fibrosis by targeting S100A4 via AMPK-STAT3 axis. Front. Pharmacol. 2023, 14, 1089812. [Google Scholar] [CrossRef]
- Kheirollahi, V.; Wasnick, R.M.; Biasin, V.; Vazquez-Armendariz, A.I.; Chu, X.; Moiseenko, A.; Weiss, A.; Wilhelm, J.; Zhang, J.-S.; Kwapiszewska, G.; et al. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nat. Commun. 2019, 10, 2987. [Google Scholar] [CrossRef]
- Lei, R.; Zhang, S.; Wang, Y.; Dai, S.; Sun, J.; Zhu, C. Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway. Int. J. Med. Sci. 2019, 16, 960–966. [Google Scholar] [CrossRef]
- Kim, J.M.; Yoo, H.; Kim, J.Y.; Oh, S.H.; Kang, J.W.; Yoo, B.R.; Han, S.Y.; Kim, C.S.; Choi, W.H.; Lee, E.J.; et al. Metformin Alleviates Radiation-Induced Skin Fibrosis via the Downregulation of FOXO3. Cell. Physiol. Biochem. 2018, 48, 959–970. [Google Scholar] [CrossRef]
- Ursini, F.; Grembiale, R.D.; D’antona, L.; Gallo, E.; D’angelo, S.; Citraro, R.; Visca, P.; Olivieri, I.; De Sarro, G.; Perrotti, N.; et al. Oral Metformin Ameliorates Bleomycin-Induced Skin Fibrosis. J. Investig. Dermatol. 2016, 136, 1892–1894. [Google Scholar] [CrossRef]
- Moon, J.; Lee, S.Y.; Choi, J.W.; Lee, A.R.; Yoo, J.H.; Moon, S.J.; Park, S.H.; Cho, M.L. Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts. J. Transl. Med. 2021, 19, 192. [Google Scholar] [CrossRef]
- Syed, F.; Sherris, D.; Paus, R.; Varmeh, S.; Pandolfi, P.P.; Bayat, A. Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor. Am. J. Pathol. 2012, 181, 1642–1658. [Google Scholar] [CrossRef]
- Zhou, X.; Liu, C.; Lu, J.; Zhu, L.; Li, M. 2-Methoxyestradiol inhibits hypoxia-induced scleroderma fibroblast collagen synthesis by phosphatidylinositol 3-kinase/Akt/mTOR signalling. Rheumatology 2018, 57, 1675–1684. [Google Scholar] [CrossRef]
- Yoshizaki, A.; Yanaba, K.; Yoshizaki, A.; Iwata, Y.; Komura, K.; Ogawa, F.; Takenaka, M.; Shimizu, K.; Asano, Y.; Hasegawa, M.; et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum. 2010, 62, 2476–2487. [Google Scholar] [CrossRef]
- Liu, Z.X.; Ji, H.; Yao, M.; Wang, L.; Wang, Y.; Zhou, P.; Liu, Y.; Zheng, X.; He, H.; Wang, L.; et al. Serum Metrnl is associated with the presence and severity of coronary artery disease. J. Cell. Mol. Med. 2019, 23, 271–280. [Google Scholar] [CrossRef]
- Gao, X.; Leung, T.-F.; Wong, G.W.-K.; Ko, W.-H.; Cai, M.; He, E.J.; Chu, I.M.-T.; Tsang, M.S.-M.; Chan, B.C.-L.; Ling, J.; et al. Meteorin-β/Meteorin like/IL-41 attenuates airway inflammation in house dust mite-induced allergic asthma. Cell. Mol. Immunol. 2022, 19, 245–259. [Google Scholar] [CrossRef]
- Hügle, T.; O’Reilly, S.; Simpson, R.; Kraaij, M.D.; Bigley, V.; Collin, M.; Krippner-Heidenreich, A.; van Laar, J.M. Tumor necrosis factor–costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthritis Rheum. 2013, 65, 481–491. [Google Scholar] [CrossRef]
- O’Reilly, S.; Hügle, T.; van Laar, J.M. T cells in systemic sclerosis: A reappraisal. Rheumatology 2012, 51, 1540–1549. [Google Scholar] [CrossRef]
Patient Number | Age (Years) | Sex | Autoantibodies | mRSS | Treatment | ILD | DLCO% |
---|---|---|---|---|---|---|---|
Patient_1 | 48 | F | Scl-70 | 9 | None | N | 85 |
Patient_2 | 54 | F | Scl-70 | 16 | None | N | 82 |
Patient_3 | 51 | F | RNA-polIII | 10 | None | N | 89 |
Patient_4 | 66 | F | Scl-70 | 16 | None | Y | 60 |
Patient_5 | 39 | F | Scl-70 | 11 | None | N | 73 |
Patient_6 | 52 | F | Scl-70 | 12 | None | N | 79 |
Patient_7 | 41 | M | Scl-70 | 19 | None | N | 87 |
Patient_8 | 49 | F | Scl-70 | 14 | None | Y | 57 |
Patient_9 | 55 | F | RNA-polIII | 17 | None | Y | 52 |
Patient_10 | 42 | F | Scl-70 | 21 | None | N | 91 |
Patient_11 | 57 | M | Scl-70 | 14 | None | N | 75 |
Patient_12 | 35 | F | Scl-70 | 19 | None | N | 82 |
Patient_13 | 47 | F | Scl-70 | 11 | None | N | 76 |
Patient_14 | 61 | F | Scl-70 | 15 | None | N | 74 |
Patient_15 | 55 | F | Scl-70 | 21 | None | Y | 50 |
Patient_16 | 37 | F | Scl-70 | 18 | None | N | 78 |
Patient_17 | 47 | F | Scl-70 | 21 | None | N | 83 |
Patient_18 | 51 | F | Scl-70 | 24 | None | N | 87 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Freedman, P.; Schock, B.; O’Reilly, S. The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis. Cells 2024, 13, 1205. https://doi.org/10.3390/cells13141205
Freedman P, Schock B, O’Reilly S. The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis. Cells. 2024; 13(14):1205. https://doi.org/10.3390/cells13141205
Chicago/Turabian StyleFreedman, Paul, Bettina Schock, and Steven O’Reilly. 2024. "The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis" Cells 13, no. 14: 1205. https://doi.org/10.3390/cells13141205
APA StyleFreedman, P., Schock, B., & O’Reilly, S. (2024). The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis. Cells, 13(14), 1205. https://doi.org/10.3390/cells13141205